title: [Acute bacterial exacerbation of chronic obstructive pulmonary disease and biofilm].
abstract: The lower respiratory tract of patients affected by COPD is constantly colonized by pathogenic microrganisms such as H. influenzae, M. catarrhalis and S. pneumoniae. Role of bacterial colonization of big and small airways in patients affected by COPD is still unclear but it is likely to play a role in directly or indirectly maintaining the vicious circle of infection/inflammation. Colonizer pathogens are capable to stimulate mucus production, to alter the ciliary function by inducing dyskinesia and stasis; in addition, they represent a strong stimulus for neutrophils to come in the airways, which release elastase that, in turn, inhibit the mucus-ciliary function. The same pathogens are responsible for epithelial damage and chronic inflammation, by releasing neutrophilic elastase, leading to the damage progression and obstruction. Recent studies have also shown that infection sustained by H. influenzae is not limited to bronchial mucosa, i.e. surface epithelial cells, but that the pathogen is capable to penetrate cells, so spreading the infection in sub-epithelial cellular layers. In addition, the ability to produce biofilm is another possible defence mechanism which allows them to grow and colonise. Such a mechanism could in part explain the lack of response to antimicrobials and contribute to stimulation of parenchymal inflammatory response, the cause of pathological-anatomic damage which occurs in COPD. The impossibility to eradicate chronic infection and bacterial exacerbations of COPD are likely the elements that promt and worsen obstruction, so determining the disease's progression.
authors.affiliation: Istituto di Malattie Respiratorie, Universita di Milano, U.O.C. Pneumologia, Ospedale L. Sacco, Milano.
authors.forename: Delfino
authors.initials: D
authors.lastname: Legnani
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D018441:Biofilms / Q000187:drug effects; D001980:Bronchi / Q000382:microbiology; D001991:Bronchitis / Q000150:complications / Q000382:microbiology* / Q000503:physiopathology / Q000821:virology; D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology; D006801:Humans; D008168:Lung / Q000382:microbiology; D045363:Pneumocystis carinii; D018410:Pneumonia, Bacterial / Q000150:complications / Q000382:microbiology; D011020:Pneumonia, Pneumocystis / Q000150:complications; D011024:Pneumonia, Viral / Q000150:complications / Q000821:virology; D017410:Practice Guidelines as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000382:microbiology* / Q000503:physiopathology
chemical_list: D000890:Anti-Infective Agents; D000975:Antioxidants; D000111:Acetylcysteine